Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002100
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Phase III Study of Curdlan Sulfate
Sponsor:
AJI Pharma USA
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Phase III Study of Curdlan Sulfate
Status:
COMPLETED
Status Verified Date:
1994-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the safety and tolerance of curdlan sulfate as well as its anti-HIV activity in HIV-infected patients with CD4 T-lymphocytes less than 500 cellsmm3 using first single doses and then after FDA review daily doses for 7 days
Detailed Description:
In Phase I of the study escalating single doses of intravenous curdlan sulfate are tested In Phase II curdlan sulfate is administered daily for 7 days NOTE Phase I is completed
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| LCPL 92-1-28 | None | None | None |